(Q52839148)

English

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

scientific article published on 28 July 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/25070546

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/25070546

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

J A Ledermann

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L Webber

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L James

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

S B Kaye

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

M Hall

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

G Hall

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

A Clamp

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

S Banerjee

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

R Kristeleit

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

F Raja

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

A Feeney

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

C Lawrence

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L Dawson-Athey

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

M Persic

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

I Khan

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

28 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/25070546

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1988-1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25070546%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Src family kinases and paclitaxel sensitivity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Microtubule dynamics are necessary for SRC family kinase-dependent growth cone steering.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU363

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52839148&oldid=1561413749"